Antibiotic treatment outcomes in community-acquired pneumonia

Simple item page
dc.contributor.authorÇilli, A
dc.contributor.authorSayiner, A
dc.contributor.authorÇelenk, B
dc.contributor.authorSakar Coskun, A
dc.contributor.authorKilinç, O
dc.contributor.authorHazar, A
dc.contributor.authorAktas Samur, A
dc.contributor.authorTasbakan, S
dc.contributor.authorWaterer, GW
dc.contributor.authorHavlucu, Y
dc.contributor.authorKiliç, Ö
dc.contributor.authorTokgöz, F
dc.contributor.authorBilge, U
dc.date.accessioned2024-07-18T12:06:28Z
dc.date.available2024-07-18T12:06:28Z
dc.description.abstractBackground/aim: The optimal empiric antibiotic regimen for patients with community-acquired pneumonia (CAP) remains unclear. This study aimed to evaluate the clinical cure rate, mortality, and length of stay among patients hospitalized with community-acquired pneumonia in nonintensive care unit (ICU) wards and treated with a beta-lactam, beta-lactam and macrolide combination, or a fluoroquinolone. Materials and methods: This prospective cohort study was perfbrined using standardized web-based database sheets from January 2009 to September 2013 in nine tertiary care hospitals in Turkey. Results: Six hundred and twenty-one consecutive patients were enrolled. A pathogen was identified in 78 (12.6%) patients. The most frequently isolated bacteria were S. pneumoniae (21.8%) and P. aeruginosa (19.2%). The clinical cure rate and length of stay were not different among patients treated with beta-lactam, beta-lactam and macrolide combination, and fluoroquinolone. Forty-seven patients (9.2%) died during the hospitalization period. There was no difference in survival among the three treatment groups. Conclusion: In patients admitted to non-ICU hospital wards for CAP, there was no difference in clinical outcomes between beta-lactam, beta-lactam and macrolide combination, and fluoroquinolone regimens.
dc.identifier.issn1300-0144
dc.identifier.other1303-6165
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/10417
dc.language.isoEnglish
dc.publisherTubitak Scientific & Technological Research Council Turkey
dc.subjectBETA-LACTAM MONOTHERAPY
dc.subjectADULTS
dc.subjectRESISTANCE
dc.subjectMACROLIDES
dc.subjectMORTALITY
dc.subjectTHERAPY
dc.subjectGUIDELINES
dc.subjectMANAGEMENT
dc.subjectPATHOGENS
dc.titleAntibiotic treatment outcomes in community-acquired pneumonia
dc.typeArticle

Files

Collections

Web of Science Koleksiyonu